What Is SS-31?
SS-31 is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-dimethylTyr-Lys-Phe-NH2. It belongs to the Szeto-Schiller (SS) family of mitochondria-targeted peptides, developed by pharmacologist Hazel Szeto at Cornell University and chemist Peter Schiller.
The peptide is also known by the pharmaceutical development name Elamipretide and the code MTP-131 (mitochondria-targeted peptide 131). It is unique among research peptides in its specific subcellular targeting: SS-31 selectively accumulates in the inner mitochondrial membrane (IMM) at concentrations hundreds to thousands of times higher than in the cytoplasm, driven by the large negative electrochemical potential across the IMM (~180 mV).
Once concentrated in the IMM, SS-31 binds cardiolipin — a phospholipid found almost exclusively in this membrane — through electrostatic and hydrophobic interactions mediated by its alternating cationic and aromatic residues.
Cardiolipin: The Target
Cardiolipin (bis(monoacylglycero)phosphate) is a dimeric phospholipid unique to the inner mitochondrial membrane in eukaryotes (and bacterial plasma membranes — an evolutionary remnant of mitochondria's bacterial ancestry). Its key biological roles:
- ETC complex stabilization: Cardiolipin physically anchors respiratory chain complexes I, III, and IV within the IMM, maintaining their quaternary structure and enabling the formation of "respirasomes" (supercomplexes of ETC components)
- Cytochrome c interaction: Cardiolipin tightly binds cytochrome c — the mobile electron carrier between complex III and IV — keeping it associated with the IMM for efficient electron transfer. When cardiolipin is oxidized, this interaction is disrupted, releasing cytochrome c into the cytoplasm where it triggers apoptosis.
- Proton gradient maintenance: The conical geometry of cardiolipin contributes to the high curvature of the IMM cristae, which concentrates protons for F0F1-ATPase (ATP synthase) activity
In aging and oxidative stress conditions, cardiolipin is preferentially oxidized — its polyunsaturated fatty acid side chains are highly susceptible to ROS attack. This cardiolipin oxidation is now recognized as a key mechanism of age-related mitochondrial dysfunction.
Mechanism of Action
SS-31's proposed mechanism is deceptively simple: by binding and protecting cardiolipin from oxidation, it restores optimal ETC function. The downstream effects documented in research:
- Restored cytochrome c binding: Prevents cytochrome c release from IMM, maintaining electron flux through complex IV and reducing electron leak to oxygen (→ less superoxide generation)
- Improved ATP synthesis efficiency: Restored ETC supercomplex formation and proton gradient integrity → higher ATP:ADP ratio
- Reduced mitochondrial ROS: By keeping electrons moving efficiently through the chain rather than leaking to form superoxide, SS-31 reduces net ROS production — measured as decreased H₂O₂ flux in isolated mitochondria
- Preserved mitochondrial membrane potential (ΔΨm): Measured by JC-1 or TMRE staining in cell culture studies
- Reduced apoptotic signalling: By retaining cytochrome c at the IMM, SS-31 reduces caspase-9/3 activation in stress conditions
Aging Research Data
SS-31 is one of the benchmark compounds in the emerging field of "mitochondrial medicine" targeting age-related bioenergetic decline. Key published findings:
Cardiac Aging
Aged mouse heart mitochondria show hallmark deficits: reduced complex I/III activity, increased ROS, reduced ATP output. In multiple published studies, acute SS-31 infusion in aged mice (24+ months) restored mitochondrial function measured ex vivo to levels comparable to young mice — described in one study as "reversing 20 years of aging" in murine cardiac bioenergetics.
Skeletal Muscle & Physical Performance
Aging is associated with reduced skeletal muscle mitochondrial capacity and decreased physical performance (VO2 max, grip strength, walking speed). Published rodent studies show SS-31 administration improved maximal mitochondrial respiration in aged skeletal muscle and increased treadmill performance in aged mice — without changes in muscle mass.
Vascular Aging
Age-related endothelial dysfunction involves mitochondrial ROS-mediated reduction of nitric oxide bioavailability. SS-31 treatment in aged mouse aortas restored endothelium-dependent vasodilation and reduced mitochondrial oxidative stress in endothelial cells — effects attributed to cardiolipin protection in vascular mitochondria.
Cardiac Protection Studies
SS-31 has been extensively studied in cardiac ischemia-reperfusion (I/R) injury models:
- I/R injury: SS-31 administered before or at reperfusion consistently reduces myocardial infarct size in rodent and pig models — one of the most replicated findings in the SS peptide literature
- Heart failure models: In pressure overload (TAC) and diabetic cardiomyopathy models, SS-31 attenuated mitochondrial dysfunction and preserved cardiac function over multi-week treatment periods
- Barth syndrome: This rare X-linked cardiomyopathy is caused by mutations in tafazzin — the enzyme that remodels cardiolipin to its mature form. It is mechanistically the most direct application for SS-31, and clinical trial data in Barth syndrome patients has shown functional improvements
Renal Protection Research
The kidney's proximal tubule cells are among the most mitochondria-rich cells in the body, making them highly susceptible to mitochondrial dysfunction. SS-31 has been studied in several renal models:
- Acute kidney injury (cisplatin-induced, I/R-induced) — attenuated tubular cell death and functional decline
- Chronic kidney disease models — slowed fibrotic progression and preserved GFR in aged rodents
- Contrast-induced nephropathy models — protective effect in animal studies
Clinical Trial History
| Trial | Indication | Phase | Result |
|---|---|---|---|
| INDIE-HFpEF | Heart failure with preserved EF | Phase II | Primary endpoint (exercise capacity) not met; positive biomarker signals |
| Barth Syndrome (TAZPOWER) | Barth syndrome cardiomyopathy | Phase II/III | Positive safety; functional improvement signals in subgroups |
| EMBRACE STEMI | Acute MI / cardiac surgery | Phase II | Completed; mixed results; ongoing analysis |
No FDA approval as of 2026. Development rights held by Stealth BioTherapeutics (various corporate history); ongoing investigation by academic and pharmaceutical groups. Rainbow Peptide supplies SS-31 For Research Use Only.
SS-31 vs MOTS-c: Mitochondrial Peptide Comparison
SS-31 and MOTS-c are the two most studied mitochondria-focused research peptides, but they work through completely different mechanisms:
- SS-31 is a synthetic peptide that physically enters the IMM and binds cardiolipin to protect ETC function. It acts directly on mitochondrial structure.
- MOTS-c is an endogenous peptide encoded in mitochondrial DNA that translocates to the nucleus under stress conditions and activates AMPK signalling — a metabolic sensor pathway. Its effects are more systemic and involve gene expression changes.
Both are available from Rainbow Peptide. Researchers studying mitochondrial bioenergetics may find SS-31 more directly mechanistic; those studying metabolic signalling and aging physiology may prefer MOTS-c or combination designs.